Chemotherapy-treated mice had lower endocannabinoid levels in their paws, and restoring them relieved pain | Research

The takeaway

Mice with chemotherapy-induced nerve pain had reduced levels of the endocannabinoid 2-AG specifically in their paw tissue, and local administration of 2-AG or a compound that prevents its breakdown relieved pain.

Cancer patients experiencing chemotherapy-induced neuropathy, oncologists seeking new pain management options, and endocannabinoid system researchers.

2-AG depleted in paw skin but not in brain or spinal cord

What the researchers found

2-AG levels were significantly reduced in the paw skin but not in the brain or spinal cord of paclitaxel-treated mice. Injecting 2-AG or the MAGL inhibitor JZL184 directly into the paw reversed pain sensitivity, and this effect required both CB1 and CB2 receptors.

Why it matters

Chemotherapy-induced neuropathic pain is a common and difficult-to-treat side effect. Finding that the endocannabinoid system is specifically depleted at the site of pain suggests targeted local treatments could help.

The numbers in context

2-AG levels were reduced only in paw skin, not in brain or spinal cord. Antiallodynic effects of 2-AG were blocked by both CB1 antagonist AM251 and CB2 antagonist AM630. Effects were limited to the injected paw only.

How the study worked

Female BALB/c mice received paclitaxel to induce mechanical allodynia. Endocannabinoid levels were measured in brain, spinal cord, and paw skin using LC-MS/MS. Local injection of 2-AG or MAGL inhibitor into the hind paw was tested for antiallodynic effects.

What this study cannot tell us

Animal study using only female mice of one strain. Endocannabinoid measurements were taken at a single time point. Local injection is not a practical delivery method for clinical use.

How to read the evidence

Well-designed preclinical study with clear mechanistic findings, but limited to a single mouse strain and sex.

When this study was published

2020 animal study. Provides mechanistic basis for potential topical cannabinoid treatments for chemo-induced neuropathy.

The bigger picture

This study suggests that chemotherapy-induced nerve pain may involve a peripheral endocannabinoid deficiency rather than a central nervous system problem, pointing toward localized rather than systemic cannabinoid treatments.

Questions still open

Do similar peripheral 2-AG deficits occur in humans with chemotherapy-induced neuropathy? Could topical cannabinoid or MAGL inhibitor formulations provide the same localized relief? Would results differ in male mice?

Common questions

What is 2-AG?

2-arachidonoyl glycerol (2-AG) is one of the body's main endocannabinoids, natural compounds that activate cannabinoid receptors. It plays roles in pain regulation, inflammation, and other processes.

Why was the endocannabinoid deficiency only in the paw?

The researchers found 2-AG was depleted only in the paw skin where nerve damage occurred, not in the brain or spinal cord. This suggests the deficit is localized to the site of injury rather than being a whole-body change.

Read the original research

Peripheral deficiency and antiallodynic effects of 2-arachidonoyl glycerol in a mouse model of paclitaxel-induced neuropathic pain.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 129, 110456

View on PubMed ↗Publisher’s paper ↗

Citation

Thomas, Amal; Okine, Bright N; Finn, David P; Masocha, Willias. (2020). Peripheral deficiency and antiallodynic effects of 2-arachidonoyl glycerol in a mouse model of paclitaxel-induced neuropathic pain.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 129, 110456. https://doi.org/10.1016/j.biopha.2020.110456